Previous 10 | Next 10 |
Aurinia Pharma (NASDAQ: AUPH ): Q2 GAAP EPS of -$0.17 misses by $0.01 . Revenue of $0.03M in-line (flat Y/Y). Shares -0.33% . Press Release More news on: Aurinia Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news,
- Fully-enrolled AURORA Phase 3 trial in lupus nephritis continues on track with results anticipated in late 2019 – - Initiating AUDREY™ Phase 2/3 clinical study for VOS in Dry Eye Syndrome – - Conference call and webcast to be hosted today at 4:30pm EDT - Auri...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that it will release its second quarter 2019 financial results on Tuesday, August 6, 2019, after the market closes. Aurinia’s management team will host a conference call to discuss the ...
Introduction RegeneRx ( OTCQB:RGRX ) is a small cap ($21M) clinical-stage biopharma developing therapeutics for tissue protection, repair and regeneration. RegeneRx has a diverse clinical pipeline comprising RGN-259 , RGN-352 and RGN-137 . The pharmacological target for RGN-137 and...
- Max Donley appointed EVP, Internal Operations and Strategy - - Glenn Schulman appointed SVP, Corporate Communications and Investor Relations - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP) (the “Company”), a late-stage clinical biopharmaceutical company with ongoi...
ILJIN SNT Co., Ltd. (“ ILJIN ”), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“ Aurinia ” or the “ Corporation ”), which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today...
Shareholders Overwhelmingly Support Aurinia and its Board of Directors Dissident Withdraws the Consents of its Nominees from Consideration Prior to the AGM Aurinia Reaffirms its Commitment to Voclosporin and Creating Shareholder Value Aurinia Pharmaceuticals Inc. (NASDAQ:AUP...
ILJIN SNT Co., Ltd. (“ ILJIN ”), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“ Aurinia ” or the “ Corporation ”), which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today...
Shareholders can vote the YELLOW proxy even if they previously voted on the green proxy Proxy voting deadline is 10:00 AM Mountain Time on Monday, June 24th Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reminde...
To ensure your vote is counted, shareholders are encouraged to vote their GREEN Proxy today in advance of the voting deadline of Friday, June 21, 2019 at 5:00 p.m. (MST) Questions? Need help? Contact call Gryphon Advisors Inc. at: 1-833-266-0365 or at inquiries@gryphonadvisors.ca . ...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...